作者:Pei-Pei Kung、Buwen Huang、Luke Zehnder、John Tatlock、Patrick Bingham、Cody Krivacic、Ketan Gajiwala、Wade Diehl、Xiu Yu、Karen A. Maegley
DOI:10.1016/j.bmcl.2015.02.017
日期:2015.4
the histone methyltransferase (HMT) inhibitor SAH (S-adenosyl-l-homocysteine). These nucleoside-based EZH2 inhibitors blocked the methylation of nucleosomes at H3K27 in biochemical assays employing both WT PRC2 complex as well as a Y641N mutant PRC2 complex. The most potent compound, 27, displayed IC50’s against both complexes of 270 nM and 70 nM, respectively. To our knowledge, compound 27 is the most
基于组蛋白甲基转移酶(HMT)抑制剂SAH(S-腺苷-1-同型半胱氨酸)的化学结构,设计了一系列新型的zeste同源物2(EZH2)抑制剂增强剂。这些基于核苷的EZH2抑制剂在同时使用WT PRC2复合物和Y641N突变体PRC2复合物的生化分析中阻止了H3K27处核小体的甲基化。最有效的化合物27对两种复合物分别显示270 nM和70 nM的IC 50值。据我们所知,化合物27是尚未发现的最有效的SAH衍生的EZH2 PRC2复合物的抑制剂。与SAH相比,该化合物还显示出更高的效价,亲脂效率(LipE)和对其他赖氨酸甲基转移酶的选择性。